Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.12% |
| 2 | Technology | 12.96% |
| 3 | Healthcare | 12.08% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Staples | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GIMO
851
DELISTED
Gigamon Inc.
GIMO
| $18.2M | 0.03% |
400,200
-390,100
| -49% | -$20.3M |
|
852
Nelnet
NNI
$4.52B
| $18.2M | 0.03% |
358,700
+10,400
| +3% | +$479K |
|
853
Lesaka Technologies
LSAK
$408M
| $18.2M | 0.03% |
1,582,700
+160,900
| +11% | +$1.77M |
|
854
Reading International Class A
RDI
$32.7M
| $18.2M | 0.03% |
1,094,400
+73,300
| +7% | +$1.07M |
|
855
Credicorp
BAP
$29.6B
| $18M | 0.03% |
114,300
+112,100
| +5,095% | +$17.2M |
|
856
Rogers Corp
ROG
$2.48B
| $18M | 0.03% |
234,900
+48,300
| +26% | +$3.27M |
|
857
Enviri
NVRI
$583M
| $18M | 0.03% |
1,323,000
+395,500
| +43% | +$4.75M |
|
858
A10 Networks
ATEN
$2B
| $18M | 0.03% |
2,164,400
+204,000
| +10% | +$1.75M |
|
|
GG
859
DELISTED
Goldcorp Inc
GG
| $18M | 0.03% |
+1,322,351
| New | +$18.4M |
|
860
Voya Financial
VOYA
$9.01B
| $18M | 0.03% |
458,300
-123,100
| -21% | -$4.34M |
|
|
WBC
861
DELISTED
WABCO HOLDINGS INC.
WBC
| $17.9M | 0.03% |
169,100
+92,200
| +120% | +$9.64M |
|
|
XL
862
DELISTED
XL Group Ltd.
XL
| $17.9M | 0.03% |
481,300
-108,700
| -18% | -$3.9M |
|
863
Brunswick
BC
$5.21B
| $17.9M | 0.03% |
328,600
+253,300
| +336% | +$12.5M |
|
|
AMAG
864
DELISTED
AMAG Pharmaceuticals
AMAG
| $17.9M | 0.03% |
+513,500
| New | +$15.3M |
|
865
Pathward Financial
CASH
$1.78B
| $17.8M | 0.03% |
518,700
-57,600
| -10% | -$1.61M |
|
|
HRG
866
DELISTED
HRG Group, Inc.
HRG
| $17.7M | 0.03% |
1,136,800
-118,500
| -9% | -$1.81M |
|
867
Qualcomm
QCOM
$173B
| $17.6M | 0.03% |
+269,760
| New | +$18.1M |
|
868
Gartner
IT
$11.6B
| $17.6M | 0.03% |
173,900
-267,000
| -61% | -$25.8M |
|
|
HTO
869
H2O America
HTO
$2.62B
| $17.6M | 0.03% |
313,700
+46,900
| +18% | +$2.37M |
|
870
XPO
XPO
$24.7B
| $17.5M | 0.03% |
+1,173,096
| New | +$16.3M |
|
|
SALE
871
DELISTED
RetailMeNot, Inc. Series 1
SALE
| $17.5M | 0.03% |
1,882,400
-117,500
| -6% | -$1.1M |
|
|
IPCC
872
DELISTED
Infinity Property & Casualty C
IPCC
| $17.5M | 0.03% |
198,700
+13,200
| +7% | +$1.12M |
|
873
Aaon
AAON
$7.03B
| $17.4M | 0.03% |
791,063
-21,300
| -3% | -$444K |
|
874
Dentsply Sirona
XRAY
$2.27B
| $17.4M | 0.03% |
301,858
+121,400
| +67% | +$7.17M |
|
|
QADA
875
DELISTED
QAD Inc.
QADA
| $17.4M | 0.03% |
573,077
-27,700
| -5% | -$728K |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.